welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”
rareRelated
-
Assessment of Cardiopulmonary Function in Duchenne Muscular DystrophyThis study seeks to develop and validate...
-
University of Minnesota Clinical Trials May Offer Hope for Local Boys With Duchenne Muscular DystrophyA rare genetic disease called Duchenne M...
-
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular DystrophyThe primary objective of this study is t...
-
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- a...Purpose: SMT C1100 is a utrophin modula...
-
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyThe main objective of this study is to e...
-
Capricor Therapeutics Expands Exosome Technology for DMDCapricor Therapeutics is expanding the d...
-
Givinostat in Duchenne’s Muscular Dystrophy Long-term Safety and Tolerability StudyThis is an open label, long-term safety,...
-
Hope in Translation: Bringing Gene Therapy to the ClinicIn 1987, scientists first uncovered the ...
-
Novel rod domain duplication in dystrophin resulting in X-linked dilated cardiomyopathyBackground: X-linked dilated cardiomyop...
